APA (7th ed.) Citation

Cherk, M. H., Kong, G., Hicks, R. J., & Hofman, M. S. (2018, January). Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. Cancer Imaging.

Chicago Style (17th ed.) Citation

Cherk, Martin H., Grace Kong, Rodney J. Hicks, and Michael S. Hofman. "Changes in Biodistribution on 68Ga-DOTA-Octreotate PET/CT After Long Acting Somatostatin Analogue Therapy in Neuroendocrine Tumour Patients May Result in Pseudoprogression." Cancer Imaging Jan. 2018.

MLA (9th ed.) Citation

Cherk, Martin H., et al. "Changes in Biodistribution on 68Ga-DOTA-Octreotate PET/CT After Long Acting Somatostatin Analogue Therapy in Neuroendocrine Tumour Patients May Result in Pseudoprogression." Cancer Imaging, Jan. 2018.